Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in
combination or sequence may have an anti-tumour activity and may reduce the risk of relapse
in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage
IV).